Monopar Therapeutics   Report issue

For profit Phase 2 Phase 3
Founded: Lake Forest CA United States (2014)
Status: No NME R&D (2014)

Organization Overview

First Clinical Trial
2019
NCT04150965
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Chief Scientific Officer | Monopar Therapeutics

Active Ingredients

Drugs in Phase 3 Trials (1)

clonidine (catapres) (1 trial)

Drugs in Phase 2 Trials (8)

Key: Monopar Therapeutics (6) Acquired (2)

13-deoxydoxorubicin (2 trials)

bms-986016 (1 trial)

bms-986207 (1 trial)

Camsirubicin (3 trials)

dexamethasone (1 trial)

elotuzumab (empliciti) (1 trial)

pomalidomide (pomalyst) (1 trial)

qa102 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Mucositis (Phase 3)

Oropharyngeal Neoplasms (Phase 3)

Stomatitis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 9